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Background: Tumors of the distal femur and diaphysis with proximal metaphyseal extension into the femur present a
challenge for limb salvage. The conventional treatment consists of limb salvage with total femur replacement. This case
study aims to present preliminary results and experience with short-stem reconstruction, focusing on the mechanical
stability of the procedure.
Methods: Sixteen short stems were implanted in 15 patients. The patients’ mean age was 33,3 years (range 11–73). In
10 patients, the stem was used for distal femur reconstruction, in one patient for diaphyseal reconstruction, and in four
for a stump lengthening procedure. All of the patients had a primary sarcoma in their history. The mean follow-up
period was 37 months (range 5–95 months). The clinical and functional follow-up data were analyzed.
Results: Ten patients (67%) were still alive at the time of evaluation. Three complications associated with the stem
were noted. In one case, there was aseptic loosening after 58 months; in another, aseptic loosening occurred because
the diameter of the stem had initially been too small; and in one case, there was breakage of the fixation screw,
without any clinical symptoms. The average Musculoskeletal Tumor Society score for all patients was 23 (range 9–28).
The mean result for the distal femur replacement was 24 (range 22–28). None of the surviving patients with distal
femur replacements needed any crutches or had a Trendelenburg limp. Both living patients who underwent a stump
lengthening procedure were able to walk with an exoprosthesis.
Conclusions: The short stem is a good solution that can prevent or delay proximal femur resection in patients with
tumors extending into the proximal metaphyseal femur. Additional risks of proximal femur resection, such as
dislocation, opening of another oncological compartment, Trendelenburg limp, and chondrolysis can be avoided.
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Tumors of the distal femur and diaphysis with proximal
metaphyseal extension into the femur present a chal-
lenge for limb salvage. The conventional treatment con-
sists of limb salvage with total femur replacement [1-6].
The disadvantage of total femur resection is that the
hip joint has to be resected. This leads to disruption of all
the muscles in the proximal femur and leads to a poorer
functional outcome, including Trendelenburg limp, in com-
parison with distal femur replacement [1,7,8]. In addition to* Correspondence: Ralf.Dieckmann@ukmuenster.de
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article, unless otherwise stated.the problems resulting from distal femur resection, a risk of
luxation of the hip is also present [4,8].
To delay or avoid resection of the hip joint in patients
with an ultrashort proximal femur shaft, we use a short
stem called the “Buxtehude stem” (Implantcast Ltd.,
Buxtehude, Germany). We use this stem in cases of distal
femur resection and for diaphyseal implants when there is
an ultrashort proximal femur shaft. We also use it for the
stump lengthening procedure. In our clinic the indication
for this stem is a proximal femur shaft with 110 mm or
less in young patients. Another indication is a bad bone
stock in case of revision. In one special case we used a
stem length of 130 mm (Figures 1).tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Aseptic loosening of the cemented stem in patient no. 5.
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sults and experience with this short stem, focusing on
the mechanical stability of the procedure.
Methods
The “Buxtehude stem” is custom made and has to be or-
dered at least 4 weeks before the planned operation. There
must be at least 40 mm of the femur left. The stem fix-
ation technique is based on three principles: Firstly, the
rib profile of the stem is for fixation in spongy bone. Sec-
ondly, the top (diameter 10 mm/length 10 mm) is fixed in
the fossa piriformis, therefore the stem length should be
at least 5 mm longer than the remaining femur. Thirdly,
screw fixation in the femoral neck avoids rotation and
enhances primary rotation stability. In the past we used
a simple 6,5 mm spongiosa screw for locking. After
breakage of the screw in patient No 2 we changed to a
8 mm locking screw (Implantcast ltd., Buxtehude). After
this methological change no further problems occurred.
A coating with hydroxylapatid is possible, but it takes atleast 2 weeks longer to produce this stem. Especially in
tumour cases the timing with chemotherapy is neces-
sary. Therefore we abandoned of coating in the past.
We had an ethics approval of the local ethic committee
of the University of Münster (2014-040-f-N). Every patient
or parents of children were informed about the study
and agreed to publish their data. A consent statement
was signed.
A total of 16 short stems were implanted in 15 patients
between 2003 and 2012. The patients’ mean age was
33,3 years (range 11–73 years). There were six female and
9 male patients. The stem was used for distal femur re-
construction in 10 patients, for diaphyseal reconstruction
in one, and for a stump lengthening procedure in four
(Figures 2, 3 and 4). For planning the stem a x-ray with
a measuring guide on the bone level was performed.
The mean follow-up period was 37 months (range 5–95
months).
All of the patients had a primary sarcoma in their his-
tory. The indication for using the short stem was a primary
tumor in seven patients, aseptic loosening of a distal femur
replacement in five, and local recurrence or intralesional
resection in four (Table 1). Stump lengthening procedures
were performed in the four patients with local recurrence
or intralesional resection (Table 2). The Enneking stage at
the time of surgery was IIb in nine patients and IIIb in six
(Table 1).
For the clinical follow-up, radiographs from the regular
follow-up were analyzed and the patients’ general practi-
tioners were contacted for further information regarding
the stage of disease, or in case of death its cause and date.
The surviving patients were contacted to obtain informa-
tion from a questionnaire assessing current symptoms,
occupation, and functional evaluation.
Functional evaluation was carried out in nine patients
using the Musculoskeletal Tumor Society (MSTS) score
[9]. Five patients had died of disease and one patient did
not want to response to the questionnaire.
Results
Oncological data
At the time of the evaluation, ten patients (67%) were
still alive. Five patients with lung metastases had died.
None of the patients developed any local recurrences
after resection of the primary sarcoma.
Surgical data
The short stem was used for distal femur replacement in
10 cases, in one case for diaphyseal reconstruction, and in
four cases for a stump lengthening procedure (Table 2).
The mean stem length was 77 mm (range 45–130 mm)
and the mean diameter of the stem was 21 mm (range
18–25 mm). The uncemented stem was fixed into the
femoral neck with a screw in all cases.
Figure 2 Patient no. 8. Distal femur replacement with short stem
and polished tibia stem.
Figure 3 Patient no. 11. Diaphyseal reconstruction.
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Three complications associated with the stem were ob-
served, as well as four complications independent of the
fixation technique (Table 2).
A screw fracture occurred in patient no. 2, with no thera-
peutic consequences. The patient also had an osteoporotic
tibial fracture. He had already had a lung metastasis at the
Figure 4 Patient no. 15. Stump lengthening procedure.
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ation of the stem.
Patient no. 5 had aseptic loosening after 58 months
and needed to be switched to a total femur replacement
(Figures 5). The patient had not had any problems be-
fore the aseptic loosening.
Early aseptic loosening occurred after 14 months in
patient no. 8. Retrospectively, the reason was found to
be that a too small stem had been implanted during the
initial operation. After revision with a thicker stem, the
patient became free of pain and had a good functional
result after 22 months.
Functional results
Due to the small number of patients and the different
indications for implantation of the stem, the results arelimited. It was possible to evaluate the MSTS score in
six patients with distal femur replacement, in one with
diaphyseal reconstruction, and in two who underwent
stump lengthening procedures. The average MSTS score
for all patients was 23 (range 9–28). Patient no. 15, with
a stump lengthening procedure, had the poorest result.
The mean result for distal femur replacement was 24
(range 22–28). None of the surviving patients with distal
femur replacement needed crutches or had a Trendelen-
burg limp. Both living patients who had undergone a
stump lengthening procedure were able to walk with an
exoprosthesis, and one of them still intermittently
needed crutches. Both patients who died had an interim
exoprosthesis. They were in bad general condition and
not able to walk, because of the oncological progression
with lung metastasis.
Discussion
Sarcomas often occur in young patients, as in the
present study. Limb salvage is nowadays possible in most
cases [8]. Because of the patients’ young age, it is neces-
sary to use an anticipatory prosthetic system. Due to the
good oncological survival rates, revision surgery of the
prostheses is unavoidable [10,11]. Distal and diaphyseal
tumors with a long proximal femoral extension are often
an indication for total femur replacement [1-6].
The complication rates with total femur replacement
are high [1,2,5,8], and the functional outcome is poorer
than with distal femur replacement [8,12]. The patients
often need crutches or other aids to walk [1]. A specific
problem with total femur replacement is dislocation,
which occurs in up to 12% of cases [1,2,5,8] and Trende-
lenburg limping [8,12]. We have increasingly used a bi-
polar head or tripolar cup, which may help to reduce
this high dislocation rate. Furthermore, when a bipolar
head is used painfull chondrolysis can occure as a long
term problem [11]. Preserving the hip joint can avoid all
these problems. In the present study the surviving pa-
tients with distal femur replacement had no need of
crutches and no risk of dislocation.
From the oncological point of view, proximal femur
resection leads to a further problem, as an additional
compartment is opened. If there is an intralesional resec-
tion or local recurrence, or if infection occurs, the hip
joint may be contaminated. To ensure wide margins in
case of local recurrence, a hemipelvectomy may be ne-
cessary. There were no cases of local recurrence in the
present study, but local recurrence rates of up to 10%
have been reported in patients with total femur replace-
ment [2,3].
Another cementless short stem solution with encour-
aging results is the Compress® implant (Fa. Biomet,
Warsaw, USA). The early aseptic loosening rate varies
from 3,8% up to 14% [13-17], but the results are limited
Table 1 Indications and stage of disease
Patient no. Age Sex Primary malignancy Metastasis Enneking stage Indication
1 11 F Ewing sarcoma Lung IIIb Primary sarcoma
2 20 M Osteosarcoma Lung IIIb Primary sarcoma
3 23 M Osteosarcoma 0 IIb Aseptic loosening
4 31 M Osteosarcoma 0 IIb Aseptic loosening
5 27 M Osteosarcoma 0 IIb Aseptic loosening
6 36 M Osteosarcoma 0 IIb Aseptic loosening
7 26 M Osteosarcoma Lung IIIb Primary sarcoma
8a 12 M Ewing sarcoma 0 IIb Primary sarcoma
8b 13 M Ewing sarcoma 0 Aseptic loosening
9 20 F Ewing sarcoma 0 IIb Primary sarcoma
10 55 M Chondrosarcoma 0 IIb Primary sarcoma
11 60 F Myxofibrosarcoma 0 IIb Primary sarcoma
12 49 M Chondrosarcoma Lung IIIb Local recurrence
13 25 F Osteosarcoma Lung IIIb Local recurrence
14 73 F Osteosarcoma Lung IIIb Intralesional resection
15 32 F Osteosarcoma 0 IIb Local recurrence
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up duration. The advantage of this system is that the
compressive osteointegration avoids stress-shielding and
save bone-stock. The standard intramedullary implant is
80 mm and was used in most of the studies [13-17]. In-







1 DOD 5 DFR 20 5
2 DOD 48 DFR 20 5
3 CDF 95 DFR 20 1
4 CDF 72 DFR 20 1
5 CDF 58 DFR 19 1
6 CDF 35 DFR 19 1
7 DOD 18 DFR 24 9
8a CDF 14 DFR 18 4
8b CDF 22 DFR 25 4
9 CDF 33 DFR 21 5
10 CDF 38 DFR 25 1
11 CDF 12 ICS 20 6
12 AWD 51 SLP 24 5
13 DOD 20 SLP 20 6
14 DOD 17 SLP 24 7
15 AWD 46 SLP 20 5
AWD, alive with disease; CDF, clinically disease-free; DFR, distal femur replacement;
Society (score); SLP, stump lengthening procedure.However, in the existing studies it is not mentioned how
often this short reconstruction is used. Furthermore there
is no example where a Compress® implant was used in
case of an ultrashort proximal femur [13-17].
Cannon et al. used a cemented approach for fixation
of short stems [18]. They used a 90° cross-pin fixation forComplications MSTS
h (mm) Associated with stem General
5 – –
5 Screw fracture Tibia fracture –
30 – –
00 – Disconnection of HMRS adapter 24
20 Aseptic loosening 24
20 Infection 22
5 –
5 Aseptic loosening –








DOD, died of disease; ICS, intercalary spacer; MSTS, Musculoskeletal Tumor
Figure 5 Patient no. 5: Aseptic loosening of the short stem in
case of revision surgery.
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proximal femoral segments. All these implants were custom
made. In 14 cases a fixation with a 135° in the proximal
femur was done. A loosening was reported in one case.
In a meta-analysis the overall aseptic loosening rate of
a distal femur replacement is 6,8% [19]. The looseningrate of the standard MUTARS distal femur replacement
with a cementless hydroxyl apatite coated stem and hex-
agonal shaft preparation is 7,7% [8]. In our small case
series we have a loosening rate of 12,5%. We think that
one reason for this is the learning curve with the im-
plant. Another reason is the short distance of anchoring
the stem with sometimes bad quality of bone. As patient
no. 5 in this study shows, using a short stem is not a
permanent solution, but it may be able to delay the im-
plantation of a total femur, with all its disadvantages, for
several years. This is important particularly for young
patients with high levels of physical activity.
Exceptional use of a short stem with a stump length-
ening procedure is a very specialized indication. How-
ever, it is known that disarticulation of the hip joint and
high-thigh amputation can lead to severe changes in func-
tion, mobility, and cosmetic appearance, and to consider-
able limitation of simple daily activities [20]. The two
surviving patients in this study were able to walk using an
exoprosthesis. Even the two patients, who died, were able
to wear an interims exoprosthesis. Although the indication
is rare, the approach can be useful in specific cases.
This study is limited by the small numbers of patients
and short follow-up periods. Large numbers of patients
in tumor surgery and homogeneous groups of patients
with this type of tumor are rare [1,2]. Despite the small
number of patients, the study showed that the mechan-
ism of implantation of this short stem works, and it pro-
vided a proof of principle for this anchor system.Conclusion
The Buxtehude short stem is a good solution that can
avoid or delay proximal femur resection in patients with
tumors extending into the proximal metaphyseal femur.
Additional risks associated with proximal femur resec-
tion, such as dislocation, opening another oncological
compartment, Trendelenburg limp, and chondrolysis can
be avoided.
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